Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Yahoo FinanceDec 22 22:11

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaDec 14 05:06

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA For Treatment Of Triple Negative Breast Cancer

BenzingaDec 3 21:12

Express News | Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA for Treatment of Triple Negative Breast Cancer (Tnbc)

BreakingsDec 3 21:00

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

BusinesswireNov 26 21:45

Express News | Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

BreakingsNov 26 21:45